Skip to content

REGEN BIOPHARMA, INC.: 10-Q filed 2024-08-13

What REGEN BIOPHARMA, INC. reported in its quarterly report filed 2024-08-13 (fiscal Q3 2024): 29 published measures, 94 facts as tagged in accession 0001607062-24-000238.

This filing

Form
10-Q (quarterly report)
Filed
2024-08-13
Fiscal period
fiscal Q3 2024
Accession
0001607062-24-000238 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All REGEN BIOPHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-06-30170,150USD
At 2023-09-30353,617USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-06-305,327,862USD
At 2023-09-305,457,617USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-06-30-5,157,712USD
At 2024-03-31-5,175,963USD
At 2023-12-31-5,241,463USD
At 2023-09-30-5,104,000USD
At 2023-06-30-5,028,973USD
At 2023-03-31-4,929,755USD
At 2022-12-31-4,884,827USD
At 2022-09-30-8,036,059USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-130,120USD91
2023-10-01 to 2024-06-30-602,353USD274
2023-04-01 to 2023-06-30-99,218USD91
2022-10-01 to 2023-06-301,481,534USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-10-01 to 2024-06-30-544,246USD274
2022-10-01 to 2023-06-30-150,512USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2024-04-01 to 2024-06-3059,065USD91
2023-10-01 to 2024-06-30177,194USD274
2023-04-01 to 2023-06-3059,065USD91
2022-10-01 to 2023-06-30177,194USD273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2024-04-01 to 2024-06-3031,640USD91
2023-10-01 to 2024-06-3094,920USD274
2023-04-01 to 2023-06-3031,640USD91
2022-10-01 to 2023-06-3094,920USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-10-01 to 2024-06-30485,058USD274
2022-10-01 to 2023-06-30100,000USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-06-30-20,351,216USD
At 2023-09-30-19,748,863USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-04-01 to 2024-06-304,213,611shares91
2023-10-01 to 2024-06-303,974,434shares274
2023-04-01 to 2023-06-303,381,366shares91
2022-10-01 to 2023-06-303,370,012shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-04-01 to 2024-06-304,213,611shares91
2023-10-01 to 2024-06-303,974,434shares274
2023-04-01 to 2023-06-303,381,366shares91
2022-10-01 to 2023-06-303,370,012shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-0.03USD/shares91
2023-10-01 to 2024-06-30-0.15USD/shares274
2023-04-01 to 2023-06-30-0.03USD/shares91
2022-10-01 to 2023-06-300.39USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-0.03USD/shares91
2023-10-01 to 2024-06-30-0.15USD/shares274
2023-04-01 to 2023-06-30-0.03USD/shares91
2022-10-01 to 2023-06-300.39USD/shares273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-10-01 to 2024-06-302,324USD274
2022-10-01 to 2023-06-30348,372USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-107,966USD91
2023-10-01 to 2024-06-30-331,819USD274
2023-04-01 to 2023-06-30-85,155USD91
2022-10-01 to 2023-06-30-627,863USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-06-30152,417USD
At 2023-09-30131,037USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-06-305,327,862USD
At 2023-09-305,308,003USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-06-3029,416USD
At 2023-09-3029,674USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2024-06-3067,147USD
At 2023-09-300USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-04-01 to 2024-06-3032,500USD91
2023-10-01 to 2024-06-30120,161USD274
2023-04-01 to 2023-06-3045,001USD91
2022-10-01 to 2023-06-30176,960USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-06-304,373,078shares
At 2023-09-303,506,366shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-06-3061,849USD
At 2023-09-30121,037USD
At 2023-06-30692USD
At 2022-09-3051,204USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-06-3014,456,692USD
At 2023-09-3013,908,141USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-130,120USD91
2024-01-01 to 2024-03-31-122,473USD91
2023-10-01 to 2023-12-31-349,760USD92
2023-04-01 to 2023-06-30-99,218USD91
2023-01-01 to 2023-03-31-54,978USD90
2022-10-01 to 2022-12-311,635,730USD92

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-117,108USD91
2023-10-01 to 2024-06-30-602,353USD274
2023-04-01 to 2023-06-30-99,218USD91
2022-10-01 to 2023-06-301,303,750USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-04-01 to 2024-06-3016,492USD91
2023-10-01 to 2024-06-3038,298USD274
2023-04-01 to 2023-06-309,262USD91
2022-10-01 to 2023-06-3036,660USD273

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2024-04-01 to 2024-06-3017,554USD91
2023-10-01 to 2024-06-3052,382USD274
2023-04-01 to 2023-06-3014,063USD91
2022-10-01 to 2023-06-3043,507USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2023-10-01 to 2024-06-3067,148USD274
2022-10-01 to 2023-06-30-197,725USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2023-10-01 to 2024-06-30-258USD274
2022-10-01 to 2023-06-30604USD273

Inspect the source

Entity
REGEN BIOPHARMA, INC. / CIK 0001589150
Captured
2026-09-20T09:23:48.532Z
SEC response SHA-256
0bbe246b6080c7701ba978807745a4ba9de62971ab4db32e8d3e2fa2c4f26a87

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001589150.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))